We’re happy to announce that MGC Pharmaceuticals are joining Cannabis Europa London as a Bronze Sponsor.
MGC Pharmaceuticals Ltd is a European based bio-pharma company developing and supplying affordable, standardised, plant-based and phytocannabinoid-derived medicines to patients globally. The company’s founders are key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality plant and phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering backed by a clinical pipeline. Its core research is focused on treatment using phytomedicines in three core areas: Neurology, Oncology, and Autoimmune diseases – including ArtemiC™ for treatment of COVID-19 infected patients.
Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility.
This year MGC became the first medicinal cannabis company to be admitted to the main market of the London Stock Exchange.
“As ever, MGC is proud to be continuing our support of Cannabis Europa, especially in London, a hub of financial and industry activity where MGC is taking the lead in demonstrating the viability of our rapidly emerging global market for plant and phytocannabinoid based biopharma.” – Roby Zomer, Managing Director and CEO
Roby Zomer will be joining the ‘Growing Pains’ panel on 11 November to discuss whether European patient access and demand for medical cannabis could ever match that of North America.
We’re thrilled to welcome MGC Pharmaceuticals and Roby Zomer to Cannabis Europa London.
If you missed out on securing a ticket to join us in London, stream Thursday’s event live for free online. Let’s Push Things Forward.
